Showing 6041-6050 of 7384 results for "".
- NEWA®, Home-Use RF Skin-Care System Launches From Eclipsehttps://practicaldermatology.com/news/newa-home-use-rf-skin-care-system-launches-from-eclipse/2458350/The DIY at-home beauty device market is exploding, and Eclipse Aesthetics®, LLC., in partnership with EndyMed Medical Ltd., is upping the ante with the
- New Lipedema Fellowship Launcheshttps://practicaldermatology.com/news/new-lipedema-fellowship-launches/2458352/The Lipedema Society is launching an International Surgical Fellowship Program. Led by dermatologic surgeon David Amron, MD, medical director of the Roxbury Institute in Beverly Hills, Calif., the six-month fellowship will equip surgeons with the necessary knowledge, tools and methods req
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- New Combo Therapy Beats Out Gold Standard Treatment For AKshttps://practicaldermatology.com/news/new-combo-therapy-beats-out-gold-standard-treatment-for-aks/2458360/Combining a cream formulation of 5-fluorouracil with a synthetic form of vitamin D called calcipotriol may trigger a robust immune response against actinic keratosis, according to research out of rom Washington University School of Medicine in St. Louis and Harvard Medical School in Boston.
- Beauty Drinks Poised to Be Cosmeceutical Industry's Next Billion-Dollar Babyhttps://practicaldermatology.com/news/beauty-drinks-poised-to-be-cosmeceutical-industrys-next-billion-dollar-baby/2458361/Beauty drinks are everywhere today, and many youth seekers turning to them as a way to improve skin and get their glow on from the inside out. In fact, beauty drinks are slated to become a billion dollar market, according to a new
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies
- Food Allergy Linked to Early Exposure Through Broken Skinhttps://practicaldermatology.com/news/food-allergy-linked-to-early-exposure-through-broken-skin/2458369/Early exposure to a food allergen through broken skin might prompt the development of food allergy, according to new research in Allergy and Asthma Proceedings. This theory gained further support from a recent study that fo
- FDA Clears Syneron Candela's Profound SubQ to Improve Cellulitehttps://practicaldermatology.com/news/fda-clears-syneron-candelas-profound-subq-to-improve-cellulite/2458381/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh
- Bob Rhatigan Joins ALASTIN Skincare's Board of Directorshttps://practicaldermatology.com/news/bob-rhatigan-joins-alastin-skincares-board-of-directors/2458384/Bob Rhatigan is joining ALASTIN Skincare™, Inc’s Board of Directors effective December 2016. Mr. Rhatigan most recently served as President and Chief Operating Officer at Alphaeon Corporation. Prior to this, he spent 17 years at Allergan In
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu